VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study - UTU Research Portal

A1 Refereed original research article in a scientific journal

VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study

Authors: Visuri MT, Honkonen KM, Hartiala P, Tervala TV, Halonen PJ, Junkkari H, Knuutinen N, Yla-Herttuala S, Alitalo KK, Saarikko AM

Publisher: SPRINGER

Publication year: 2015

Journal: Angiogenesis

Journal name in source: ANGIOGENESIS

Journal acronym: ANGIOGENESIS

Volume: 18

Issue: 3

First page : 313

Last page: 326

Number of pages: 14

ISSN: 0969-6970

DOI: https://doi.org/10.1007/s10456-015-9469-2

Abstract

Conclusions Our results show that VEGF-C provides the preferred alternative for growth factor therapy of lymphedema when compared to VEGF-C156S, due to the superior lymphangiogenic response and minor blood vessel effects. Furthermore, these observations suggest that activation of both VEGFR-2 and VEGFR-3 might be needed for efficient lymphangiogenesis.